Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection

German giant Bayer has teamed up with investment firm Versant Ventures to launch a new stem cell company with $225m in start-up funding.

New company BlueRock Therapeutics, funded by $225m of series A cash from Bayer AG and Versant Ventures, is based on a new stem cell platform and will have an initial focus on cardiovascular diseases and neurodegenerative disorders.

The stem cell platform at BlueRock has been assembled through a series of partnerships with academic and industry collaborators in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip